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Abstract
Recent advances in deep learning and specifically in generative adversarial  networks have
demonstrated surprising results in generating new images and videos upon request even using
natural language as input. In this paper we present the first application of generative adversarial
autoencoders  (AAE)  for  generating  novel  molecular  fingerprints  with  a  defined  set  of
parameters. We developed a 7-layer AAE architecture with the latent middle layer serving as a
discriminator.  As  an  input  and  output  the  AAE  uses  a  vector  of  binary  fingerprints  and
concentration of the molecule. In the latent layer we also introduced a neuron responsible for
growth inhibition percentage, which when negative indicates the reduction in the number of
tumor cells after the treatment. To train the AAE we used the NCI-60 cell line assay data for
6252 compounds profiled on MCF-7 cell line. The output of the AAE was used to screen 72
million  compounds  in  PubChem and  select  candidate  molecules  with  potential  anticancer
properties. This approach is a proof of concept of an artificially-intelligent drug discovery engine,
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